Legal DealFolio - Sanofi Definitive Agreement for Acquisition of Ablynx

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement under which Sanofi offered to acquire all of the outstanding ordinary shares, which represented an aggregate equity value of approximately EUR3.9 billion. Linklaters advised Ablynx on the deal.

Deal Date:	05-02-2018	Practice Area:	Corporate and M&A
Deal Title:	Sanofi Definitive Agreement for Acquisition of Ablynx	Industry:	Pharmaceuticals & Biotechnology
Description:	Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, entered into a definitive agreement under which Sanofi offered to acquire all of the outstanding ordinary shares, which represented an aggregate equity value of approximately EUR3.9 billion. Linklaters advised Ablynx on the deal.
Financial Center:	Brussels	Value:	1000.01-5000.00
Advised Party:	Target Company	Law Firm	Linklaters
Target Company Jurisdiction:	Belgium	Acquiror Jurisdiction:	Belgium
Classification:	Strategic Buyer Acquisitions Private Company	Lawyer	Arnaud Coibion

Practice Areas -

Corporate and M&A Law Firms and Lawyers

Practice Areas - Corporate and M&A Law Firms and Lawyers